Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
ST. LOUIS, May 22, 2024 BUSINESS WIRE )--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the United States District Court for the District of Delaware dismissed Exact Sciences' claim of infringement regarding United States Patent No. 11,634,781 ("the '781 patent"). The Court's ruling concluded that the allegations did not support a claim that Geneoscopy has infringed, or currently is infringing, the ‘781 patent. The Court's order directed Exact Sciences to file an amended complaint. It also denied certain technical objections Geneoscopy raised related to other claims. At this stage of the litigation, the Court did not address, nor was it asked to determine, whether the ‘781 patent is valid or enforceable. "At Geneoscopy, our goal is to advance RNA biomarker technology to provide accurate, reliable screening solutions for detecting CRC and advanced adenomas," said Andrew Barnell,
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $80.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Exact Sciences: Still No Reason To Own [Seeking Alpha]Seeking Alpha
- Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Exact Sciences (NASDAQ:EXAS) shareholders have endured a 63% loss from investing in the stock three years ago [Yahoo! Finance]Yahoo! Finance
- UltraSight and Mayo Clinic join forces for AI-driven cardiac care [Yahoo! Finance]Yahoo! Finance
EXAS
Earnings
- 5/8/24 - Miss
EXAS
Sec Filings
- 6/25/24 - Form 11-K
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- EXAS's page on the SEC website